The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (laBCC) or metastatic basal cell carcinoma (mBCC).
 
Julie E. Stein
Research Funding - Bristol-Myers Squibb (Inst)
 
Patricia Brothers
Research Funding - Bristol-Myers Squibb
 
Katie Applebaum
No Relationships to Disclose
 
Angela Gaskin
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Janis M. Taube
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck
 
Evan J. Lipson
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Macrogenics; Merck; Millennium; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Sysmex (Inst)
Patents, Royalties, Other Intellectual Property - METHOD OF PREVENTING ORGAN TRANSPLANT REJECTIONS USING AGONISTS TO THE PD-1 CHECKPOINT PATHWAY (Inst)